微小RNA：胆管癌中新的调节分子与生物标志物

国际肿瘤学杂志››2016,Vol. 43››Issue (11): 865-867.doi:10.3760/cma.j.issn.1673-422X.2016.11.017

微小RNA：胆管癌中新的调节分子与生物标志物

吴雄波，安方梅，占强

214023南京医科大学附属无锡人民医院消化内科

收稿日期:2016-04-05出版日期:2016-11-08发布日期:2016-11-02
通讯作者:占强，Email: zhanq33@163.com E-mail:占强，Email: zhanq33@163.com
基金资助:

国家自然科学基金（81502038）；江苏省自然科学基金（BK2012098）

MicroRNAs： the emerging regulatory molecules and biomarkers of cholangiocarcinoma

Wu Xiongbo, An Fangmei, Zhan Qiang

Department of Gastroenterology, Wuxi People′s Hospital Affiliated to Nanjing Medical University, Wuxi 214023, China

Received:2016-04-05Online:2016-11-08Published:2016-11-02
Contact:占强，Email: zhanq33@163.com E-mail:占强，Email: zhanq33@163.com
Supported by:

National Natural Science Foundation of China (81502038); Natural Science Foundation of Jiangsu Province of China (BK2012098)

摘要/Abstract

摘要：微小RNA（miRNA）与胆管癌（CCA）的发生发展、浸润、转移和预后密切相关。CCA细胞中异常表达的miRNA在调控细胞遗传变异、细胞周期、浸润转移能力及其凋亡过程中起重要作用，有望作为CCA早期诊断、预后判断的生物学标志物及治疗靶点。

吴雄波，安方梅，占强. 微小RNA：胆管癌中新的调节分子与生物标志物[J]. 国际肿瘤学杂志, 2016, 43(11): 865-867.

Wu Xiongbo, An Fangmei, Zhan Qiang. MicroRNAs： the emerging regulatory molecules and biomarkers of cholangiocarcinoma[J]. Journal of International Oncology, 2016, 43(11): 865-867.

［1］ Braconi C, Huang N, Patel T. MicroRNAdependent regulation of DNA methyltransferase1 and tumor suppressor gene expression by interleukin 6 in human malignant cholangiocytes［J］. Hepatology, 2010, 51(3): 881-890. DOI: 10.1002/hep.23381. ［2］ An F, Yamanaka S, Allen S, et al. Silencing of miR370 in human cholangiocarcinoma by allelic loss and interleukin 6 induced maternal to paternal epigenotype Switch［J］. PLoS One, 2012, 7(10): e45606. DOI: 10.1371/journal.pone.0045606. ［3］ Bueno MJ, Malumbres M. MicroRNAs and the cell cycle［J］. Biochim Biophys Acta, 2011, 1812(5): 592-601. DOI: 10.1016/j.bbadis.2011.02.002. ［4］ Zhong XY, Yu JH, Zhang WG, et al. MicroRNA421 functions as an oncogenic miRNA in biliary tract cancer through downregulating farnesoid X receptor expression［J］. Gene, 2012, 493(1): 44-51. DOI: 10.1016/j.gene.2011.11.028. ［5］ Olaru AV, Ghiaur G, Yamanaka S, et al. MicroRNA downregulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint［J］. Hepatology, 2011, 54(6): 20892098. DOI: 10.1002/hep.24591. ［6］ Yamanaka S, Campbell NR, An F, et al. Coordinated effects of microRNA494 induce G2/M arrest in human cholangiocarcinoma［J］. Cell Cycle, 2012, 11(14): 2729-2738. DOI: 10.4161/cc.21105. ［7］ An F, Olaru AV, Mezey E, et al. MicroRNA224 induces G1/S checkpoint release in liver cancer［J］. J Clin Med, 2015, 4(9): 17131728. DOI: 10.3390/jcm4091713. ［8］ Namwat N, Chusorn P, Loilome W, et al. Expression profiles of oncomir miR21 and tumor suppressor let7a in the progression of opisthorchiasisassociated cholangiocarcinoma［J］. Asian Pac J Cancer Prev, 2012, 13(Suppl): 65-69. ［9］ Chang Y, Liu C, Yang J, et al. MiR-20a triggers metastasis of gallbladder carcinoma［J］. J Hepatol, 2013, 59(3): 518-527. DOI: 10.1016/j.jhep.2013.04.034. ［10］ Zeng B, Li Z, Chen R, et al. Epigenetic regulation of miR124 by hepatitis C virus core protein promotes migration and invasion of intrahepatic cholangiocarcinoma cells by targeting SMYD3［J］. FEBS Lett, 2012, 586(19): 32713278. DOI: 10.1016/j.febslet.2012.06.049. ［11］ Qiu YH, Wei YP, Shen NJ, et al. miR204 inhibits epithelial to mesenchymal transition by targeting slug in intrahepatic cholangiocarcinoma cells［J］. Cell PhysiolBiochem, 2013, 32(5): 13311341. DOI: 10.1159/000354531. ［12］ Selaru FM, Olaru AV, Kan T, et al. MicroRNA21 is overexpressed in human cholangiocarcinoma and regulates programmed cell death 4 and tissue inhibitor of metalloproteinase 3［J］. Hepatology, 2009, 49(5): 1595-1601. DOI: 10.1002/hep.22838. ［13］ Wang Q, Tang H, Yin S, et al. Downregulation of microRNA-138 enhances the proliferation, migration and invasion of cholangiocarcinoma cells through the upregulation of RhoC/p-ERK/MMP-2/MMP9［J］. Oncol Rep, 2013, 29(5): 20462052. DOI: 10.3892/or.2013.2304. ［14］ Peng F, Jiang J, Yu Y, et al. Direct targeting of SUZ12/ROCK2 by miR200b/c inhibits cholangiocarcinoma tumourigenesis and metastasis［J］. Br J Cancer, 2013, 109(12): 3092-3104. DOI: 10.1038/bjc.2013.655. ［15］李知翰, 张西亮, 汪伟. 微小RNA126与血管内皮生长因子在胃癌中的表达及意义［J］. 国际肿瘤学杂志, 2015, 42(12): 900-902. DOI: 10.3760/cma.j.issn.1673-422X.2015.12.005. ［16］ Iwaki J, Kikuchi K, Mizuguchi Y, et al. MiR376c downregulation accelerates EGFdependent migration by targeting GRB2 in the HuCCT1 human intrahepatic cholangiocarcinoma cell line［J］. PLoS One, 2013, 8(7): e69496. DOI: 10.1371/journal.pone.0069496. ［17］ Si ML, Zhu S, Wu H, et al. miR21mediated tumor growth［J］. Oncogene, 2007, 26(19): 2799-2803. DOI: 10.1038/sj.onc.1210083. ［18］ Razumilava N, Bronk SF, Smoot RL, et al. miR25 targets TNFrelated apoptosis inducing ligand (TRAIL) death receptor4 and promotes apoptosis resistance in cholangiocarcinoma［J］. Hepatology, 2012, 55(2): 465475. DOI: 10.1002/hep.24698. ［19］ Hu C, Huang F, Deng G, et al. miR31 promotes oncogenesis in intrahepatic cholangiocarcinoma cells via the direct suppression of RASA1［J］. Exp Ther Med, 2013, 6(5): 1265-1270. DOI: 10.3892/etm.2013.1311. ［20］ Mott JL, Kobayashi S, Bronk SF, et al. mir29 regulates Mcl1 protein expression and apoptosis［J］. Oncogene, 2007, 26(42): 6133-6140. DOI: 10.1038/sj.onc.1210436. ［21］ Meng F, Henson R, Lang M, et al. Involvement of human microRNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines［J］. Gastroenterology, 2006, 130(7): 2113-2129. DOI: 10.1053/j.gastro.2006.02.057. ［22］ Bernuzzi F, Marabita F, Lleo A, et al. Serum microRNAs as novel biomarkers for primary sclerosing cholangitis and cholangiocarcinoma［J］. ClinExpImmunol, 2016, 185(1): 61-71. DOI: 10.1111/cei.12776. ［23］唐秋, 胡巧英. 肿瘤标志物循环微小RNA的临床研究现状［J］. 国际肿瘤学杂志, 2015, 42(11): 832834. DOI: 10.3760/cma.j.issn.1673422X.2015.11.009. ［24］ Shigehara K, Yokomuro S, Ishibashi O, et al. Realtime PCRbased analysis of the human bile microRNAome identifies miR9 as a potential diagnostic biomarker for biliary tract cancer［J］. PLoS One, 2011, 6(8): e23584. DOI: 10.1371/journal.pone.0023584. ［25］ Kawahigashi Y, Mishima T, Mizuguchi Y, et al. MicroRNA profiling of human intrahepatic cholangiocarcinoma cell lines reveals biliary epithelial cellspecific microRNAs［J］. J Nippon Med Sch, 2009, 76(4): 188-197. ［26］ Collins AL, Wojcik S, Liu J, et al. A differential microRNA profile distinguishes cholangiocarcinoma from pancreatic adenocarcinoma［J］. Ann SurgOncol, 2014, 21(1): 133-138. DOI: 10.1245/s10434-013-3240-y. ［27］黄敏丹, 吴雄波, 曹慧, 等. 血清miR224调控胆管上皮癌细胞的侵袭及转移作用［J］. 中华肝脏病杂志, 2015, 23(10): 748-753. DOI: 10.3760/cma.j.issn.1007-3418.2015.10.008. ［28］ Peng HH, Zhang YD, Gong LS, et al. Increased expression of microRNA335 predicts a favorable prognosis in primary gallbladder carcinoma［J］. Onco Targets Ther, 2013, 6: 1625-1630. DOI: 10.2147/OTT.S53030. ［29］ Jin K, Xiang Y, Tang J, et al. miR34 is associated with poor prognosis of patients with gallbladder cancer through regulating telomere length in tumor stem cells［J］. TumourBiol, 2014, 35(2): 15031510. DOI: 10.1007/s132770131207z. ［30］ Mcnally ME, Collins A, Wojcik SE, et al. Concomitant dysregulation of microRNAs miR-151-3p and miR-126 correlates with improved survival in resected cholangiocarcinoma［J］. HPB (Oxford), 2013, 15(4): 260-264. DOI: 10.1111/j.1477-2574.2012.00523.x. ［31］ Hummel R, Hussey DJ, Haier J. MicroRNAs: predictors and modifiers of chemo and radiotherapy in different tumour types［J］. Eur J Cancer, 2010, 46(2): 298-311. DOI: 10.1016/j.ejca.2009.10.027. ［32］ Okamoto K, Miyoshi K, Murawaki Y. miR29b, miR-205 and miR-221 enhance chemosensitivity to gemcitabine in HuH28 human cholangiocarcinoma cells［J］. PLoS One, 2013, 8(10): e77623. DOI: 10.1371/journal.pone.0077623.

[1]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛.索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[2]	龚艳, 陈洪雷.微RNA调控卵巢癌顺铂耐药的机制研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 186-190.
[3]	黄辉, 丁江华.靶向FGFR2治疗晚期胆管癌的研究进展[J]. 国际肿瘤学杂志, 2023, 50(9): 569-573.
[4]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳.沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[5]	周仁邦, 张仲传, 许志远, 朱勋兵.miR-219a-5p通过负调控HMGA2抑制骨肉瘤U2OS细胞增殖、侵袭和迁移[J]. 国际肿瘤学杂志, 2022, 49(4): 193-198.
[6]	金嘉会, 陈存海, 马学真.放射相关miRNA在乳腺癌放疗中的作用[J]. 国际肿瘤学杂志, 2022, 49(12): 735-738.
[7]	井文君, 赵文文, 冯青青, 赵文飞, 赵丽丽, 张雪, 魏红梅.miR-34家族用于胃癌治疗的分子基础及临床前景[J]. 国际肿瘤学杂志, 2022, 49(11): 681-686.
[8]	罗丽云, 赖灿辉, 梁仁佩, 杨爱武, 林志敏.晚期胃癌中miR-524-5p与SOX9表达的相关性及其对化疗疗效和预后的影响[J]. 国际肿瘤学杂志, 2022, 49(1): 45-50.
[9]	刘佩, 蒲嘉泽, 黄雯, 汪斐.吉非替尼敏感与耐药NSCLC患者miR-200c、miR-19a、miR-155表达差异及其对患者预后的影响[J]. 国际肿瘤学杂志, 2021, 48(7): 409-414.
[10]	王阳, 刘芊, 龙辉, 吴清明.结直肠癌标志物粪便检测的研究现状[J]. 国际肿瘤学杂志, 2021, 48(7): 441-444.
[11]	程一鸣, 李刚, 王振明, 吕倩文, 李世荣.血清miR-196a-5p、miR-105-5p在良恶性肺结节鉴别诊断中的价值[J]. 国际肿瘤学杂志, 2021, 48(5): 282-286.
[12]	邓波儿, 孔为民.子宫内膜癌的表观遗传学研究进展[J]. 国际肿瘤学杂志, 2021, 48(3): 184-188.
[13]	李炳亮, 杨娅, 黄英丽, 司文, 李兴伟, 张元民, 卞继超, 陈语.miR-20a-5p靶向KDM6B对骨肉瘤细胞增殖、迁移和侵袭能力的影响[J]. 国际肿瘤学杂志, 2021, 48(2): 65-73.
[14]	何苗, 范奎, 曹芳.表观遗传与肺癌耐药[J]. 国际肿瘤学杂志, 2021, 48(10): 622-626.
[15]	张敏, 周丽娜, 徐姗姗, 陈骏.肿瘤免疫治疗相关预测生物标志物研究进展[J]. 国际肿瘤学杂志, 2020, 47(8): 487-491.